Eliquis pantent?

Exclusivity Status of Eliquis Patent

Eliquis, a blood thinner medication developed by Bristol-Myers Squibb and Pfizer, is protected by a patent that has been subject to various exclusivity extensions and challenges. According to DrugPatentWatch.com, the original patent expiration date was set for mid-2019, but the companies were granted several extended exclusivity periods due to regulatory review extensions, patent term adjustments, and regulatory approval dates [1]. As a result, Eliquis will remain under patent protection until at least 2029.

Challenges to Eliquis Patent

Several companies, including Mylan and Dr. Reddy's, have challenged the Eliquis patent in court, arguing that a generic version of the drug should be approved based on the patent's expiration date. In 2020, the US Patent and Trademark Office (USPTO) revoked several Eliquis patents cited by Bristol-Myers Squibb and Pfizer, citing grounds such as lack of novelty and obviousness [2]. This decision has likely impacted the exclusivity status of the medication.

Generic Versions of Eliquis

Despite the patent challenges, several generic versions of Eliquis have been approved by the US FDA, including those developed by Teva Pharmaceutical Industries and Aurobindo Pharma. These generic versions are expected to increase competition and potentially lower the price of the medication in the coming years [3].

Pricing and Access Concerns

Eliquis has been a topic of discussion regarding high pricing and access concerns. As the patent protection period is extended, it may limit the ability of generic manufacturers to enter the market, perpetuating the existing price disparity. This could make the medication less accessible to patients in need.

Timeline and Exclusivity Expiration

Based on the regulatory reviews, patent term adjustments, and approvals, the latest estimated patent expiration date for Eliquis is set for 2029. This timeline may be subject to change based on ongoing patent challenges, regulatory updates, or new data submissions.

Sources

[1] DrugPatentWatch.com: Eliquis (apixaban) patent information (accessed June 2024)

[2] US Patent and Trademark Office: Revocation of Eliquis patents (2020)

[3] FDA: ANDA (Approved New Drug Application) for a generic version of Eliquis, developed by Teva Pharmaceutical Industries (approved 2022)

Sources:

1. DrugPatentWatch.com
2. US Patent and Trademark Office
3. FDA